WO2001087329A8 - Liquid pharmaceutical composition containing an erythropoietin derivate - Google Patents
Liquid pharmaceutical composition containing an erythropoietin derivateInfo
- Publication number
- WO2001087329A8 WO2001087329A8 PCT/EP2001/005187 EP0105187W WO0187329A8 WO 2001087329 A8 WO2001087329 A8 WO 2001087329A8 EP 0105187 W EP0105187 W EP 0105187W WO 0187329 A8 WO0187329 A8 WO 0187329A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- erythropoietin
- derivate
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0110914A BRPI0110914B8 (en) | 2000-05-15 | 2001-05-08 | 'liquid pharmaceutical composition, process for its preparation and use of a pharmaceutical composition' |
AU65934/01A AU784091B2 (en) | 2000-05-15 | 2001-05-08 | New pharmaceutical composition |
PL361341A PL219131B1 (en) | 2000-05-15 | 2001-05-08 | Novel pharmaceutical composition |
KR1020027015429A KR100758044B1 (en) | 2000-05-15 | 2001-05-08 | New pharmaceutical composition |
SI200130331T SI1311285T1 (en) | 2000-05-15 | 2001-05-08 | |
ES01943331.7T ES2237574T5 (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical composition containing an erythropoietin derivative |
PT01943331T PT1311285E (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical composition containing a derivative of erythropoietin |
AT01943331T ATE291436T2 (en) | 2000-05-15 | 2001-05-08 | LIQUID MEDICINAL PREPARATION CONTAINING AN ERYTHROPOIETIN DERIVATIVE |
IL15265901A IL152659A0 (en) | 2000-05-15 | 2001-05-08 | Pharmaceutical composition |
NZ522030A NZ522030A (en) | 2000-05-15 | 2001-05-08 | Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition |
DK01943331.7T DK1311285T4 (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical composition containing an erythropoietin derivative |
MXPA02011303A MXPA02011303A (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical composition containing an erythropoietin derivate. |
MEP-907/08A MEP90708A (en) | 2000-05-15 | 2001-05-08 | New pharmaceutical composition |
JP2001583796A JP3967594B2 (en) | 2000-05-15 | 2001-05-08 | New pharmaceutical composition |
KR1020077003371A KR20070032815A (en) | 2000-05-15 | 2001-05-08 | New pharmaceutical composition |
CA2408685A CA2408685C (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical composition containing an erythropoietin derivate |
DE60109625.8T DE60109625T3 (en) | 2000-05-15 | 2001-05-08 | LIQUID MEDICINE PREPARATION CONTAINING AN ERYTHROPOIETIN DERIVATIVE |
EP01943331.7A EP1311285B2 (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical composition containing an erythropoietin derivative |
HU0302114A HU230874B1 (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical compositions stable at room temperature which comprising a pegylated human erythropoietin protein |
IL152659A IL152659A (en) | 2000-05-15 | 2002-11-05 | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer |
HR20020880A HRP20020880B1 (en) | 2000-05-15 | 2002-11-07 | New pharmaceutical composition |
NO20025450A NO330934B1 (en) | 2000-05-15 | 2002-11-14 | Liquid pharmaceutical composition and its use and preparation. |
HK03109033A HK1056683A1 (en) | 2000-05-15 | 2003-12-11 | New pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00110355 | 2000-05-15 | ||
EP00110355.5 | 2000-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001087329A1 WO2001087329A1 (en) | 2001-11-22 |
WO2001087329A8 true WO2001087329A8 (en) | 2002-03-07 |
Family
ID=8168722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/005187 WO2001087329A1 (en) | 2000-05-15 | 2001-05-08 | Liquid pharmaceutical composition containing an erythropoietin derivate |
Country Status (36)
Country | Link |
---|---|
US (2) | US7169754B2 (en) |
EP (2) | EP1311285B2 (en) |
JP (1) | JP3967594B2 (en) |
KR (3) | KR20070032815A (en) |
CN (1) | CN1309416C (en) |
AR (2) | AR035034A1 (en) |
AT (1) | ATE291436T2 (en) |
AU (1) | AU784091B2 (en) |
BR (1) | BRPI0110914B8 (en) |
CA (1) | CA2408685C (en) |
CZ (1) | CZ304855B6 (en) |
DE (1) | DE60109625T3 (en) |
DK (1) | DK1311285T4 (en) |
EC (2) | ECSP024352A (en) |
ES (1) | ES2237574T5 (en) |
HK (1) | HK1056683A1 (en) |
HR (1) | HRP20020880B1 (en) |
HU (1) | HU230874B1 (en) |
IL (2) | IL152659A0 (en) |
JO (1) | JO3404B1 (en) |
MA (1) | MA26901A1 (en) |
ME (1) | MEP90708A (en) |
MX (1) | MXPA02011303A (en) |
MY (1) | MY128654A (en) |
NO (1) | NO330934B1 (en) |
NZ (1) | NZ522030A (en) |
PE (1) | PE20020050A1 (en) |
PL (1) | PL219131B1 (en) |
PT (1) | PT1311285E (en) |
RS (1) | RS51292B (en) |
RU (1) | RU2281116C2 (en) |
SI (1) | SI1311285T1 (en) |
TW (2) | TWI288644B (en) |
UY (1) | UY26704A1 (en) |
WO (1) | WO2001087329A1 (en) |
ZA (1) | ZA200208500B (en) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US7304150B1 (en) * | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
CZ299516B6 (en) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
AU2001264563A1 (en) * | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2408685C (en) * | 2000-05-15 | 2011-02-01 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivate |
DE60144439D1 (en) * | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG) |
JP4656814B2 (en) | 2000-12-20 | 2011-03-23 | エフ.ホフマン−ラ ロシュ アーゲー | Erythropoietin conjugate |
FR2823220B1 (en) * | 2001-04-04 | 2003-12-12 | Genodyssee | NOVEL ERYTHROPOIETIN (EPO) POLYNUCLEOTIDES AND POLYPEPTIDES |
EP1401477A4 (en) * | 2001-05-25 | 2005-02-02 | Human Genome Sciences | Chemokine beta-1 fusion proteins |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
JP2003152145A (en) * | 2001-08-31 | 2003-05-23 | Sumitomo Electric Ind Ltd | Semiconductor heat dissipating substrate, method for its manufacture, and package |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
CA2484556A1 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
MXPA04012496A (en) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Pegylated factor vii glycoforms. |
SI21258A (en) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stable pharmaceutical preparation containing erythropoietin and poloxamer polyol |
US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
JP2006511468A (en) * | 2002-09-09 | 2006-04-06 | ウォーレン ファーマシューティカルズ,インコーポレーテッド | Long-acting erythropoietin maintains the tissue protective activity of endogenous erythropoietin |
ZA200502320B (en) * | 2002-09-20 | 2006-10-25 | Pharmacia Corp | Process for decreasing aggregate levels of pegylated protein |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7803777B2 (en) * | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US20080146782A1 (en) * | 2006-10-04 | 2008-06-19 | Neose Technologies, Inc. | Glycerol linked pegylated sugars and glycopeptides |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
AU2004240553A1 (en) * | 2003-05-09 | 2004-12-02 | Neose Technologies, Inc. | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
MXPA05012314A (en) * | 2003-05-12 | 2006-04-18 | Affymax Inc | Spacer moiety for poly(ethylene glycol) -modified peptides. |
KR101163683B1 (en) * | 2003-05-12 | 2012-07-10 | 아피맥스, 인크. | Novel peptides that bind to the erythropoietin receptor |
EA010099B1 (en) * | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Novel peptides that bind to the erythropoietin receptor and methods for use thereof |
WO2004101600A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel poly(ethylene glycol) modified compounds and uses thereof |
MXPA05013398A (en) | 2003-06-10 | 2006-03-09 | Lg Life Sciences Ltd | Stable, aqueous solution of human erythropoietin, not containing serum albumin. |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
KR20060120141A (en) * | 2003-11-24 | 2006-11-24 | 네오스 테크놀로지스, 인크. | Glycopegylated erythropoietin |
US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
NZ547554A (en) * | 2003-12-03 | 2009-09-25 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
SI1696947T1 (en) | 2003-12-19 | 2014-05-30 | F. Hoffmann-La Roche Ag | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
WO2005070138A2 (en) * | 2004-01-08 | 2005-08-04 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
EP1718664A4 (en) * | 2004-02-02 | 2008-08-13 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
DE102004011663B4 (en) * | 2004-03-10 | 2006-04-27 | Bioceuticals Arzneimittel Ag | Erythropoietin liquid formulation |
US20050282751A1 (en) * | 2004-03-19 | 2005-12-22 | Ajinomoto Co., Inc. | Therapeutic agent for renal anemia |
JPWO2005089743A1 (en) * | 2004-03-19 | 2008-01-31 | 味の素株式会社 | Treatment for renal anemia |
CA2561222A1 (en) * | 2004-03-26 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Combination dosing regimen for erythropoietin |
AR049580A1 (en) * | 2004-07-07 | 2006-08-16 | Lundbeck & Co As H | CARBAMILATED EPO AND METHOD FOR YOUR PRODUCTION |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
WO2006020372A2 (en) * | 2004-07-23 | 2006-02-23 | Neose Technologies, Inc. | Enzymatic modification of glycopeptides |
US20060029551A1 (en) * | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
EP1799249A2 (en) * | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
CA2585758C (en) | 2004-10-29 | 2017-08-01 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
JP2006137678A (en) * | 2004-11-10 | 2006-06-01 | Shionogi & Co Ltd | Interleukin-2 composition |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
EP1814910A4 (en) * | 2004-11-11 | 2009-04-29 | Affymax Inc | Novel peptides that bind to the erythropoietin receptor |
US20100009902A1 (en) * | 2005-01-06 | 2010-01-14 | Neose Technologies, Inc. | Glycoconjugation Using Saccharyl Fragments |
ES2449195T3 (en) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Glycopegylated granulocyte colony stimulating factor |
CA2595676A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
EP1866427A4 (en) * | 2005-03-30 | 2010-09-01 | Novo Nordisk As | Manufacturing process for the production of peptides grown in insect cell lines |
US20070154992A1 (en) * | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070037886A1 (en) * | 2005-04-26 | 2007-02-15 | Ajinomoto Co., Inc. | Bone marrow erythroid progenitor cell(s) differentiation inducer |
WO2006127910A2 (en) * | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7790679B2 (en) * | 2005-08-05 | 2010-09-07 | Amgen Inc. | Pharmaceutical formulations |
EP1937719A4 (en) * | 2005-08-19 | 2010-11-24 | Novo Nordisk As | Glycopegylated factor vii and factor viia |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
US20090048440A1 (en) * | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
ES2839549T3 (en) | 2005-11-23 | 2021-07-05 | Acceleron Pharma Inc | Activin-ActRIIa antagonists for use in stimulating bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CN101015684B (en) * | 2006-02-10 | 2011-08-24 | 华北制药集团新药研究开发有限责任公司 | Recombinant erythropoietin liquor preparation |
JP5553506B2 (en) * | 2006-03-22 | 2014-07-16 | 中外製薬株式会社 | Erythropoietin solution formulation |
WO2008011633A2 (en) * | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
KR101304081B1 (en) * | 2006-08-04 | 2013-09-05 | 프로롱 파마슈티컬스, 엘엘씨 | Modified erythropoietin |
WO2008057683A2 (en) * | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
US20080207487A1 (en) * | 2006-11-02 | 2008-08-28 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
TW202104248A (en) | 2007-02-02 | 2021-02-01 | 美商艾瑟勒朗法瑪公司 | Variants derived from actriib and uses therefor |
PL2144923T3 (en) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
US20080286341A1 (en) * | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered coated nicotine containing products |
WO2008151258A2 (en) * | 2007-06-04 | 2008-12-11 | Neose Technologies, Inc. | O-linked glycosylation using n-acetylglucosaminyl transferases |
ES2551123T3 (en) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Improved process for the production of nucleotide sugars |
WO2009002521A2 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
CL2008002054A1 (en) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Method for the regeneration of a cation exchange chromatography column after elusion of monopeglated erythropoietin and method to obtain a monopeglated erythropoietin, incorporating the regeneration method of the cation exchange column. |
CL2008002053A1 (en) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method. |
PT2197919E (en) | 2007-08-27 | 2014-07-17 | Ratiopharm Gmbh | Liquid formulation of g-csf conjugate |
US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN101456911A (en) * | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | Erythrocyte-stimulating factor mimic peptide derivative, medical salts thereof, preparation method and use thereof |
JP5647899B2 (en) * | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | Glycoconjugation of polypeptides using oligosaccharyltransferase |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
US8058229B2 (en) | 2008-08-14 | 2011-11-15 | Acceleron Pharma Inc. | Method of increasing red blood cell levels or treating anemia in a patient |
CA2736141C (en) * | 2008-09-23 | 2018-03-20 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
KR20190090049A (en) | 2009-06-12 | 2019-07-31 | 악셀레론 파마 인코포레이티드 | TRUNCATED ActRIIB-FC FUSION PROTEINS |
CA2764934A1 (en) | 2009-06-24 | 2010-12-29 | F. Hoffmann-La Roche Ag | Characterization of re-useable chromatography equipment |
BRPI0902481B8 (en) * | 2009-07-31 | 2021-05-25 | Soc Beneficente De Senhoras Hospital Sirio Libanes | pharmaceutical composition comprising hemopressin and its use. |
EP2464369B1 (en) * | 2009-08-13 | 2020-03-11 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
US20120264688A1 (en) * | 2009-09-23 | 2012-10-18 | Walter Hinderer | Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same |
AU2010322011B2 (en) | 2009-11-17 | 2016-03-31 | Acceleron Pharma Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
JP5621052B2 (en) | 2010-12-21 | 2014-11-05 | エフ.ホフマン−ラ ロシュアーゲーF.Hoffmann−La Roche Aktiengesellschaft | Chromatographic equipment characterization |
AR094821A1 (en) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION |
CN102816227A (en) * | 2012-08-30 | 2012-12-12 | 深圳赛保尔生物药业有限公司 | Erythropoietin recovery method |
RU2018145985A (en) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | ACTIVIN-ACTRII ANTAGONISTS AND THEIR APPLICATION FOR TREATMENT OF BONE TISSUE DISORDERS AND OTHER DISORDERS |
CU20140003A7 (en) | 2014-01-08 | 2015-08-27 | Ct De Inmunología Molecular Biofarmacuba | CONJUGATE UNDERSTANDING ERYTHROPOYETIN AND A RAMIFIED POLYMER STRUCTURE |
CA2943906A1 (en) | 2014-03-29 | 2015-10-08 | Intas Pharmaceuticals Ltd. | Liquid pharmaceutical composition of conjugated erythropoietin |
BR122023023170A2 (en) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2018184692A1 (en) * | 2017-04-07 | 2018-10-11 | Ares Trading S.A. | Liquid pharmaceutical composition |
HRP20220388T1 (en) * | 2017-12-29 | 2022-05-27 | F. Hoffmann - La Roche Ag | Process for providing pegylated protein composition |
CN111558046A (en) * | 2020-05-27 | 2020-08-21 | 华润昂德生物药业有限公司 | Application of trehalose in preparation of recombinant human erythropoietin liquid preparation, preparation method and application |
TWI740635B (en) * | 2020-09-09 | 2021-09-21 | 財團法人工業技術研究院 | Polyvinylidene fluoride film composition, and polyvinylidene fluoride isolation film |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US115833A (en) * | 1871-06-13 | Improvement in grain-driers | ||
US147431A (en) * | 1874-02-10 | Improvement in game boards | ||
JPS6197229A (en) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
DE3729863A1 (en) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | STABILIZED ERYTHROPOIETIN LYOPHILISATES |
DE3734923C1 (en) | 1987-10-15 | 1989-01-26 | Biotest Pharma Gmbh | Process for the preparation of a sterile plasma protein solution containing fibrinogen and coagulation factor XIII |
DE4014654A1 (en) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | GALENIC AQUEOUS FORMULATIONS OF ERYTHROPOIETIN AND THEIR USE |
CA2069746A1 (en) * | 1990-09-28 | 1992-03-29 | Jonathan I. Rosen | Hybrid growth factors |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
US5460944A (en) | 1991-10-28 | 1995-10-24 | Boehringer Mannheim Gmbh | Storable protein solution |
DE4135542A1 (en) | 1991-10-28 | 1993-04-29 | Boehringer Mannheim Gmbh | STORAGE PROTEIN SOLUTIONS |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
IL192290A0 (en) * | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
ATE341344T1 (en) † | 1996-08-02 | 2006-10-15 | Ortho Mcneil Pharm Inc | POLYPEPTIDES WITH SINGLE COVALENTLY BONDED N-TERMINAL WATER SOLUBLE POLYMER |
US5919656A (en) | 1996-11-15 | 1999-07-06 | Amgen Canada Inc. | Genes encoding telomerase protein 1 |
EP0885613A1 (en) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Use of modified hemoglobins for treatment of anemias and erythropoietin and modified hemoglobin containing combined preparations |
DE19734293A1 (en) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Use of pharmaceutical combination preparations containing erythropoietin and iron preparations for the treatment of rheumatic diseases |
ES2347884T3 (en) | 1998-10-23 | 2010-11-22 | Amgen Inc. | METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE ANEMIA. |
UY25790A1 (en) | 1998-11-06 | 2000-08-21 | Bio Sidus S A | PHARMACEUTICAL FORMS OF RECOMBINANT HUMAN ERYTHROPOYETIN STABLE AT ROOM TEMPERATURE AND SUITABLE FOR USE IN HUMANS, FORMULATIONS AND FREEZE PROCEDURES FOR THEIR OBTAINING. |
JP2000247903A (en) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | Long-term stabilized pharmaceutical preparation |
CA2369444C (en) † | 1999-04-09 | 2009-08-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmaceutical compositions of erythropoietin |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
PE20010288A1 (en) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | ERYTHROPOYETIN DERIVATIVES |
CZ299516B6 (en) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
WO2001007075A2 (en) | 1999-07-22 | 2001-02-01 | Aventis Pharmaceuticals, Inc. | Multi-dose erythropoietin formulations |
EP1232753B1 (en) † | 1999-09-08 | 2008-03-19 | Chugai Seiyaku Kabushiki Kaisha | Stable protein solution filled in a container made from a hydrophobic resin and method of stabilizing the same |
US7163671B2 (en) | 2000-02-29 | 2007-01-16 | Chugai Seiyaku Kabushiki Kaisha | Long-term stabilized formulations |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
CA2408685C (en) * | 2000-05-15 | 2011-02-01 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivate |
EP1336410A4 (en) † | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | Protein injection preparations |
JP4656814B2 (en) * | 2000-12-20 | 2011-03-23 | エフ.ホフマン−ラ ロシュ アーゲー | Erythropoietin conjugate |
US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
-
2001
- 2001-05-08 CA CA2408685A patent/CA2408685C/en not_active Expired - Lifetime
- 2001-05-08 RS YUP-835/02A patent/RS51292B/en unknown
- 2001-05-08 KR KR1020077003371A patent/KR20070032815A/en not_active Application Discontinuation
- 2001-05-08 PL PL361341A patent/PL219131B1/en unknown
- 2001-05-08 CZ CZ2002-4005A patent/CZ304855B6/en not_active IP Right Cessation
- 2001-05-08 IL IL15265901A patent/IL152659A0/en unknown
- 2001-05-08 PT PT01943331T patent/PT1311285E/en unknown
- 2001-05-08 RU RU2002133236/15A patent/RU2281116C2/en active
- 2001-05-08 CN CNB018095607A patent/CN1309416C/en not_active Expired - Lifetime
- 2001-05-08 AT AT01943331T patent/ATE291436T2/en active
- 2001-05-08 ES ES01943331.7T patent/ES2237574T5/en not_active Expired - Lifetime
- 2001-05-08 KR KR1020057023568A patent/KR20050121762A/en not_active Application Discontinuation
- 2001-05-08 EP EP01943331.7A patent/EP1311285B2/en not_active Expired - Lifetime
- 2001-05-08 MX MXPA02011303A patent/MXPA02011303A/en active IP Right Grant
- 2001-05-08 BR BRPI0110914A patent/BRPI0110914B8/en not_active IP Right Cessation
- 2001-05-08 DE DE60109625.8T patent/DE60109625T3/en not_active Expired - Lifetime
- 2001-05-08 ME MEP-907/08A patent/MEP90708A/en unknown
- 2001-05-08 JP JP2001583796A patent/JP3967594B2/en not_active Expired - Lifetime
- 2001-05-08 WO PCT/EP2001/005187 patent/WO2001087329A1/en not_active Application Discontinuation
- 2001-05-08 EP EP05000984A patent/EP1525889A1/en not_active Withdrawn
- 2001-05-08 SI SI200130331T patent/SI1311285T1/xx unknown
- 2001-05-08 AU AU65934/01A patent/AU784091B2/en active Active
- 2001-05-08 KR KR1020027015429A patent/KR100758044B1/en active IP Right Grant
- 2001-05-08 HU HU0302114A patent/HU230874B1/en unknown
- 2001-05-08 DK DK01943331.7T patent/DK1311285T4/en active
- 2001-05-08 NZ NZ522030A patent/NZ522030A/en not_active IP Right Cessation
- 2001-05-09 JO JOP/2001/0065A patent/JO3404B1/en active
- 2001-05-11 PE PE2001000421A patent/PE20020050A1/en active IP Right Grant
- 2001-05-11 US US09/853,731 patent/US7169754B2/en not_active Expired - Lifetime
- 2001-05-11 MY MYPI20012197A patent/MY128654A/en unknown
- 2001-05-11 AR ARP010102248A patent/AR035034A1/en not_active Application Discontinuation
- 2001-05-14 UY UY26704A patent/UY26704A1/en not_active IP Right Cessation
- 2001-05-14 TW TW094134688A patent/TWI288644B/en not_active IP Right Cessation
- 2001-05-14 TW TW090111453A patent/TWI288643B/en not_active IP Right Cessation
-
2002
- 2002-10-21 ZA ZA200208500A patent/ZA200208500B/en unknown
- 2002-11-05 IL IL152659A patent/IL152659A/en active IP Right Grant
- 2002-11-07 HR HR20020880A patent/HRP20020880B1/en not_active IP Right Cessation
- 2002-11-13 MA MA26907A patent/MA26901A1/en unknown
- 2002-11-14 NO NO20025450A patent/NO330934B1/en not_active IP Right Cessation
- 2002-11-20 EC EC2002004352A patent/ECSP024352A/en unknown
-
2003
- 2003-12-11 HK HK03109033A patent/HK1056683A1/en unknown
-
2004
- 2004-02-17 US US10/780,297 patent/US7202208B2/en not_active Expired - Lifetime
-
2010
- 2010-12-21 EC EC2010004352A patent/ECSP10004352A/en unknown
-
2013
- 2013-10-04 AR ARP130103618A patent/AR092919A2/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001087329A8 (en) | Liquid pharmaceutical composition containing an erythropoietin derivate | |
WO2001098290A3 (en) | Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
BR0109650A (en) | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | |
WO2002047715A3 (en) | Compositions of peptide crystals | |
CA2319308A1 (en) | Pharmaceutical agents | |
MXPA04000920A (en) | Aminoisoxazole derivatives active as kinase inhibitors. | |
EP1820503A3 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
BG101118A (en) | Therapeutical compounds | |
PL374325A1 (en) | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof | |
PL374443A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
WO2001034641A3 (en) | Antimicrobial activity of the first cationic cluster of human lactoferrin | |
WO2003051838A3 (en) | Protein kinase inhibitors | |
MXPA02011533A (en) | NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE. | |
WO2002000208A3 (en) | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents | |
UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
CA2387600A1 (en) | Novel fusidic acid derivatives | |
WO2002070537A3 (en) | Fusidic acid derivatives | |
AU5494298A (en) | Pharmaceutical compositions for the treatment of the eye | |
IL160160A0 (en) | SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS | |
WO2003040119A8 (en) | Angiogenesis inhibitors | |
WO1999019324A3 (en) | Antipsychotic substituted piperidine derivatives | |
WO2002100346A3 (en) | (r, r'),(r',s')-amphetaminil, compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-835/02 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522030 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/08500 Country of ref document: ZA Ref document number: 200208500 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 152659 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65934/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20020880A Country of ref document: HR Ref document number: 2001943331 Country of ref document: EP Ref document number: IN/PCT/2002/1827/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2408685 Country of ref document: CA Ref document number: 02102350 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/011303 Country of ref document: MX Ref document number: 1020027015429 Country of ref document: KR Ref document number: 018095607 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-4005 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2002133236 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027015429 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001943331 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-4005 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 522030 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 522030 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001943331 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027015429 Country of ref document: KR |